Terms: = Sarcomas AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
3 results:
1. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term outcomes, and Effects of Early Chemotherapy.
Nyirenda M; Ngongondo M; Kang M; Umbleja T; Krown SE; Godfrey C; Samaneka W; Mngqibisa R; Hoagland B; Mwelase N; Caruso S; Martinez-Maza O; Dittmer DP; Borok M; Hosseinipour MC; Campbell TB;
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):422-429. PubMed ID: 32265361
[TBL] [Abstract] [Full Text] [Related]
2. Selective resistance to the PARP inhibitor olaparib in a mouse model for brca1-deficient metaplastic breast cancer.
Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
[TBL] [Abstract] [Full Text] [Related]
3. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract] [Full Text] [Related]
